Description
Kerendia (finerenone) is a prescription medication used to treat chronic kidney disease (CKD) in adults with type 2 diabetes. It is a non-steroidal, selective mineralocorticoid receptor antagonist that works by blocking the effects of the hormone aldosterone, which can contribute to kidney damage. By reducing aldosterone levels, Kerendia can improve kidney function and reduce the risk of kidney failure, cardiovascular events, and death.
Uses:
Kerendia is used to treat chronic kidney disease (CKD) in adults with type 2 diabetes.
Storage Conditions:
Kerendia should be stored at room temperature between 68°F and 77°F (20°C and 25°C) in its original container. It should be protected from moisture and light.
Mechanism of Action:
Kerendia (finerenone) is a non-steroidal, selective mineralocorticoid receptor antagonist that works by blocking the effects of the hormone aldosterone, which can contribute to kidney damage. By reducing aldosterone levels, Kerendia can improve kidney function and reduce the risk of kidney failure, cardiovascular events, and death.
HOW TO USE:
Kerendia should be taken orally, once daily, with or without food. The recommended starting dose is 10 mg per day, with dosages adjustments based on individual response and tolerance. Patients should take the medication at the same time each day. If a dose is missed, it should be taken as soon as possible, but not later than 12 hours before the next scheduled dose.
Precautions:
• Patients should inform their healthcare provider of any medical conditions they have, especially liver problems, heart failure, and gout.
• Kerendia may increase the risk of hyperkalemia, a condition in which there is too much potassium in the blood. Patients should be monitored for signs and symptoms of hyperkalemia.
• Kerendia may interact with other medications, including angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), potassium-sparing diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs). Patients should inform their healthcare provider of all the medications they are taking before starting Kerendia.
Drug Interactions:
• Kerendia may interact with other medications, including angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), potassium-sparing diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs).
• Patients should inform their healthcare provider of all the medications they are taking before starting Kerendia.
Contraindications:
• Kerendia should not be used in patients with hypersensitivity to the medication or its components.
• It is not recommended for use in patients with severe liver impairment or end-stage kidney disease.
• Kerendia should not be used concomitantly with potassium-sparing diuretics or potassium supplements.
Overdose:
There is limited information on the overdose of Kerendia. However, patients who take a higher-than-prescribed dosage of Kerendia should seek medical attention immediately.
Adverse Reactions:
The most common adverse reactions experienced by patients taking Kerendia include hyperkalemia, hypotension, and hyponatremia. Other potential side effects include dizziness, diarrhea, and anemia. Patients should contact their healthcare provider if they experience any unusual symptoms while taking Kerendia.
In conclusion, Kerendia (finerenone) is a non-steroidal, selective mineralocorticoid receptor antagonist that treats chronic kidney disease (CKD) in adults with type 2 diabetes by reducing aldosterone levels. Patients should take the medication orally once daily, with starting dosage recommendations at 10 mg per day, and dosage adjustments based on response and tolerance. Before taking Kerendia, patients should inform their healthcare provider of any medical conditions they have or medication they are taking, especially liver problems, heart failure, and gout. Adverse reactions may include hyperkalemia, hypotension, hyponatremia, dizziness, diarrhea, and anemia. Kerendia should not be used by those with hypersensitivity to the medication or its components, severe liver impairment, end-stage kidney disease, or patients taking potassium-sparing diuretics or potassium supplements.
Reviews
There are no reviews yet.